Innovent Biologics, Inc. (“Innovent”), a leading biopharmaceutical company, has appointed Dr. Samuel Zhang as its Global Chief Business Officer (CBO). With over 20 years of experience in the industry, Dr. Zhang will lead Innovent’s global strategy and business development efforts, working closely with Dr. Michael Yu, the founder, Chairman, and CEO of the company.
Dr. Zhang’s impressive track record includes successful partnerships and strategic transactions in leading biopharmaceutical and biotech companies. His expertise in identifying emerging trends and assets, developing fast-to-market strategies, and delivering value in competitive markets will further enhance Innovent’s position in the global pharmaceutical landscape.
Prior to joining Innovent, Dr. Zhang held key roles at Gracell Biotechnologies and NeoImmuneTech, leading to a $1.2B acquisition by AstraZeneca. His educational background includes a Ph.D. in Molecular Biology from Columbia University, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.S. in Biology from Peking University.
Dr. Yu expressed excitement over Dr. Zhang’s appointment, highlighting the company’s focus on corporate development and global partnerships. Innovent, founded in 2011, is dedicated to providing affordable high-quality biologics to treat cancer, cardiovascular and metabolic, autoimmune, and eye diseases. With 10 products in the market, multiple drug applications under review, and strategic partnerships with global healthcare companies, including Eli Lilly and Sanofi, Innovent is committed to advancing the accessibility of first-rate pharmaceutical drugs.
Driven by the motto “Start with Integrity, Succeed through Action,” Innovent upholds the highest industry standards and encourages collaborative efforts within the biopharmaceutical sector. Dr. Zhang’s appointment aligns with the company’s vision to pioneer new science and develop breakthrough medicines to meet critical patient needs worldwide.
For more information about Innovent and its innovative therapies, visit http://www.innoventbio.com or connect with Innovent on Facebook and LinkedIn.
Please note that some products mentioned, such as TYVYT®, BYVASDA®, HALPRYZA®, SULINNO®, and Pemazyre®, are not approved in the United States. Innovent does not recommend the use of any unapproved drugs or indications.
This news release may contain forward-looking statements, and readers are advised to consult Innovent’s official sources for the most up-to-date information regarding the company’s developments and initiatives.
Source link
